AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma
暂无分享,去创建一个
J. Gribben | J. Leonard | I. Flinn | P. Scheinberg | K. Izutsu | F. Re | P. Fustier | Jun Zhu | M. Trněný | A. Scheliga | F. Offner | G. Nowakowski | N. Fowler | X. Hong | J. Cabeçadas | L. Fogliatto | A. Pinto | Chengqing Wu | C. Moreira | Huilai Zhang | David R. Liu | S. Kalambakas | G. Nowakowski
[1] P. Moreau,et al. Progression of disease within 2 years (POD24) is a clinically significant endpoint to identify follicular lymphoma patients with high risk of death. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[2] G. Salles,et al. Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma , 2018, The New England journal of medicine.
[3] P. Zinzani,et al. Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[4] A. Valderrama,et al. Treatment patterns among elderly follicular lymphoma patients diagnosed between 2000 and 2011: An analysis of linked SEER-Medicare data. , 2017 .
[5] J. Cerhan,et al. 2016 US lymphoid malignancy statistics by World Health Organization subtypes , 2016, CA: a cancer journal for clinicians.
[6] J. Gribben,et al. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. , 2016, The Lancet. Oncology.
[7] M. Ghielmini,et al. Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] M. Stauch,et al. Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial. , 2016, The Lancet. Oncology.
[9] M. Czuczman,et al. Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance). , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] Thomas J. Smith,et al. Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] Alexandre F. Carisey,et al. Lenalidomide augments actin remodeling and lowers NK-cell activation thresholds. , 2015, Blood.
[12] S. Schuster,et al. Combination of Lenalidomide and Rituximab Overcomes Rituximab Resistance in Patients with Indolent B-cell and Mantle Cell Lymphomas , 2015, Clinical Cancer Research.
[13] J. Friedberg,et al. Transformed follicular non-Hodgkin lymphoma. , 2015, Blood.
[14] Michael L. Wang,et al. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. , 2014, The Lancet. Oncology.
[15] R. Gascoyne,et al. Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol e4402. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] J. Tuscano,et al. Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non‐Hodgkin lymphoma , 2014, British journal of haematology.
[17] R. Stephens,et al. Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial. , 2014, The Lancet. Oncology.
[18] G. Salles,et al. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. , 2014, The New England journal of medicine.
[19] H. Handa,et al. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4CRBN , 2013, British journal of haematology.
[20] K. Izutsu. Treatment of follicular lymphoma. , 2014, Journal of clinical and experimental hematopathology : JCEH.
[21] Sonali M. Smith. Dissecting follicular lymphoma: high versus low risk. , 2013, Hematology. American Society of Hematology. Education Program.
[22] N. Schmitz,et al. ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[23] S. Karasawa,et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide , 2012, Leukemia.
[24] D. Esseltine,et al. Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial. , 2011, The Lancet. Oncology.
[25] J. Cerhan,et al. Second-line therapy in follicular lymphoma in the United States: Report of NLCS observational study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] J. Crawford,et al. Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[27] M. Calaminici,et al. Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy. , 2009, Blood.
[28] George Muller,et al. Lenalidomide Enhances Natural Killer Cell and Monocyte-Mediated Antibody-Dependent Cellular Cytotoxicity of Rituximab-Treated CD20+ Tumor Cells , 2008, Clinical Cancer Research.
[29] M. Czuczman,et al. Immunomodulatory drugs stimulate natural killer‐cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti‐tumour activity of rituximab in vivo , 2007, British journal of haematology.
[30] Sigrid Stroobants,et al. Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] M. Czuczman,et al. Immunomodulatory Drug CC-5013 or CC-4047 and Rituximab Enhance Antitumor Activity in a Severe Combined Immunodeficient Mouse Lymphoma Model , 2005, Clinical Cancer Research.
[32] M. Cairo,et al. Tumour lysis syndrome: new therapeutic strategies and classification , 2004, British journal of haematology.
[33] M. Ghielmini,et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. , 2004, Blood.
[34] J. Hainsworth,et al. Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] M. Czuczman,et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] R. Levy,et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] James Olen Armitage,et al. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. , 1997, Blood.
[38] T. Lister,et al. Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .